Namibia Approves Twice-Yearly HIV Prevention Shot

Namibia just became one of the first African nations to approve a revolutionary HIV prevention drug that could change the game for millions of people at risk.

The Ministry of Health and Social Services registered lenacapavir, an injectable medication that provides HIV protection with just two doses per year. That's a massive shift from current oral PrEP drugs that require taking a pill every single day.

Thousands of Namibians already use daily PrEP pills to prevent HIV infection. The new twice-yearly option removes the challenge of remembering daily medication, which could help more people stay protected consistently.

Namibia has already achieved impressive HIV care milestones. The country hit all three UNAIDS 95-95-95 targets, meaning 95% of people living with HIV know their status, 95% of those diagnosed receive treatment, and 95% of those on treatment have suppressed the virus.

But new infections continue happening. Across sub-Saharan Africa, about 4,000 adolescent girls and young women acquired HIV every week in 2024.

Health Minister Esperance Luvindao celebrated the approval while acknowledging a serious obstacle. The drug's current global price sits at over $28,000 per person per year, roughly 441,655 Namibian dollars.

"Innovation without equity is not enough," Luvindao said. "Access to cutting-edge health technologies must not be a privilege for the few. It must be available to all, regardless of where you come from or how much money you have in your bank account."

The ministry is now working with the African Medicines Agency to negotiate price reductions. The goal is making lenacapavir affordable enough to integrate into public health programs without overwhelming national budgets.

The Ripple Effect

When prevention becomes easier, more people use it. A twice-yearly shot could protect individuals who struggle with daily pills due to stigma, complicated schedules, or simply forgetting. That means fewer new infections, healthier communities, and less strain on healthcare systems already managing HIV treatment programs.

Namibia's fast-track approval also sends a signal to pharmaceutical companies that African nations are ready for innovative solutions and willing to be early adopters when treatments truly serve their populations.

The country's willingness to both approve the drug and publicly push for fair pricing shows how health equity battles are fought: celebrate the science, then demand access for everyone who needs it.